Literature DB >> 19275211

Drugs of abuse that mediate advanced glycation end product formation: a chemical link to disease pathology.

Jennifer B Treweek1, Tobin J Dickerson, Kim D Janda.   

Abstract

Nicotine and methamphetamine are frequently abused in modern society, despite the increasing evidence of their addictive, neuropharmacological, and toxic effects. Tobacco, the most widely abused substance, is the leading cause of preventable death in the United States, killing nearly half a million Americans annually. A methamphetamine epidemic has also spread during the past decade; severe neurotoxicity and addictiveness contribute to the drug's notoriety. Although the majority of research on these two drugs is of pharmacological and neurobiological motivation, further study of these molecules from a chemical perspective may provide novel mechanistic insight into either their addictive potential or their pathological effects. For example, nicotine and methamphetamine share a common structural feature, a secondary amine, suggesting that these molecules could possess similar (or analogous) in vivo reactivity. Discoveries concerning the synthetic requirements for aqueous aldol catalysis and the feasibility of the enamine mechanism under physiological conditions have given rise to the hypothesis that ingested molecules, such as abused drugs, could participate in reactions utilizing an enamine intermediate in vivo. The chemical reactivity of exogenous drugs with amine functionalities was initially examined in the context of the Maillard reaction, or nonenzymatic browning. The heating of reducing sugars with amino acids yields a brown solution; studies of this reaction were originally applied to food chemistry for the production of distinct flavors and aromas. Further research has since revealed numerous instances in which the in vivo production of advanced glycation end products (AGEs) through the Maillard reaction contribute to the pathology of disease states. Specifically, the modification of long-lived proteins by glycation and glycoxidation and the accumulation of these AGEs compromise the original function of such proteins and change the mechanical properties of affected tissue. In this Account, we summarize our investigations into the capacity for exogenous compounds to initiate the Maillard reaction and the corresponding physiological and immunological impact of the drug-conjugated AGEs that form. Many of the pathological components of diabetes, atherosclerosis, cancer, macular degeneration, Alzheimer's disease, and even the normal aging process are attributable to AGEs and their potential for aggregate formation in the vasculature. A deeper understanding of AGEs, and particularly glycated proteins, will provide fundamental mechanistic insight into disease origins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275211      PMCID: PMC2982794          DOI: 10.1021/ar800247d

Source DB:  PubMed          Journal:  Acc Chem Res        ISSN: 0001-4842            Impact factor:   22.384


  48 in total

1.  Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism.

Authors:  C Saunders; J V Ferrer; L Shi; J Chen; G Merrill; M E Lamb; L M Leeb-Lundberg; L Carvelli; J A Javitch; A Galli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells.

Authors:  N Tanaka; H Yonekura; S Yamagishi; H Fujimori; Y Yamamoto; H Yamamoto
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

3.  Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus.

Authors:  Z Turk; S Ljubic; N Turk; B Benko
Journal:  Clin Chim Acta       Date:  2001-01       Impact factor: 3.786

4.  N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.

Authors:  T Kislinger; C Fu; B Huber; W Qu; A Taguchi; S Du Yan; M Hofmann; S F Yan; M Pischetsrieder; D Stern; A M Schmidt
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

5.  FTIR monitoring of oxazolidin-5-one formation and decomposition in a glycolaldehyde-phenylalanine model system by isotope labeling techniques.

Authors:  Fong Lam Chu; Varoujan A Yaylayan
Journal:  Carbohydr Res       Date:  2008-10-18       Impact factor: 2.104

6.  Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine.

Authors:  P H Schaiberger; T C Kennedy; F C Miller; J Gal; T L Petty
Journal:  Chest       Date:  1993-08       Impact factor: 9.410

7.  Advanced glycation end products contribute to amyloidosis in Alzheimer disease.

Authors:  M P Vitek; K Bhattacharya; J M Glendening; E Stopa; H Vlassara; R Bucala; K Manogue; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

8.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins.

Authors:  S D Yan; A M Schmidt; G M Anderson; J Zhang; J Brett; Y S Zou; D Pinsky; D Stern
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

9.  Role of fructose in glycation and cross-linking of proteins.

Authors:  J D McPherson; B H Shilton; D J Walton
Journal:  Biochemistry       Date:  1988-03-22       Impact factor: 3.162

10.  Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin.

Authors:  T W Lo; M E Westwood; A C McLellan; T Selwood; P J Thornalley
Journal:  J Biol Chem       Date:  1994-12-23       Impact factor: 5.157

View more
  13 in total

1.  Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.

Authors:  Natasha J McIntyre; Richard J Fluck; Christopher W McIntyre; Maarten W Taal
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

Review 2.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

Review 3.  Glial modulators as potential treatments of psychostimulant abuse.

Authors:  Patrick M Beardsley; Kurt F Hauser
Journal:  Adv Pharmacol       Date:  2014

Review 4.  Developing a vaccine against multiple psychoactive targets: a case study of heroin.

Authors:  G Neilm Stowe; Joel E Schlosburg; Leandro F Vendruscolo; Scott Edwards; Kaushik K Misra; Gery Schulteis; Joseph S Zakhari; George F Koob; Kim D Janda
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-12       Impact factor: 4.388

5.  Corticosterone and exogenous glucose alter blood glucose levels, neurotoxicity, and vascular toxicity produced by methamphetamine.

Authors:  John F Bowyer; Karen M Tranter; Sumit Sarkar; Nysia I George; Joseph P Hanig; Kimberly A Kelly; Lindsay T Michalovicz; Diane B Miller; James P O'Callaghan
Journal:  J Neurochem       Date:  2017-09-21       Impact factor: 5.372

6.  Impact of distinct chemical structures for the development of a methamphetamine vaccine.

Authors:  Amira Y Moreno; Alexander V Mayorov; Kim D Janda
Journal:  J Am Chem Soc       Date:  2011-04-07       Impact factor: 15.419

7.  Skin autofluorescence and all-cause mortality in stage 3 CKD.

Authors:  Simon D S Fraser; Paul J Roderick; Natasha J McIntyre; Scott Harris; Christopher W McIntyre; Richard J Fluck; Maarten W Taal
Journal:  Clin J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 8.237

8.  The vagus nerve mediates the suppressing effects of peripherally administered oxytocin on methamphetamine self-administration and seeking in rats.

Authors:  Nicholas A Everett; Anita J Turner; Priscila A Costa; Sarah J Baracz; Jennifer L Cornish
Journal:  Neuropsychopharmacology       Date:  2020-05-25       Impact factor: 7.853

Review 9.  Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.

Authors:  Arthur N Westover; Ethan A Halm
Journal:  BMC Cardiovasc Disord       Date:  2012-06-09       Impact factor: 2.298

10.  Strategies for Fostering Synergy between Neuroscience Programs and Chemistry Departments.

Authors:  Darin J Ulness; Julie R Mach
Journal:  J Undergrad Neurosci Educ       Date:  2011-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.